At least 23 biotechs and pharmas are slated to report earnings next week. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are expected to report more than a 50% jump in EPS on revenue growth of more than 60%. Questcor markets H.P. Acthar Gel repository corticotropin injection to treat 19 indications including nephrotic syndrome. Regeneron's Eylea aflibercept was launched in November 2011 to treat wet age-related macular degeneration (AMD). Arena Pharmaceuticals Inc. (NASDAQ: ARNA), which received FDA approval for obesity drug Belviq lorcaserin last June, is expected to swing